To make sure provide after an FDA emergency use authorization, Samsung Biologics has accelerated manufacturing of Eli Lilly’s COVID-19 antibody bamlanivimab. The South Korean CDMO and associate AstraZeneca intend to disband their biosimilar three way partnership on an absence of economic alternative. In the meantime, AstraZeneca‘s former China R&D head has launched a brand new agency with $200 million from some enterprise capital heavy hitters. And extra.
1. Lilly companions with Samsung to spice up COVID-19 antibody manufacturing amid provide considerations
Now that Eli Lilly’s AbCellera-shared COVID-19 antibody bamlanivimab has received FDA emergency use authorization, its manufacturing associate Samsung Biologics is ready to “greatly accelerate” the worldwide provide. The 2 first signed the manufacturing collaboration settlement in May, and Samsung has since produced a primary batch of the lively ingredient.
2. Samsung Biologics, AstraZeneca to dissolve biosimilar JV, scrap Rituxan copy program: report
In the meantime, Samsung Biologics and AstraZeneca are calling it quits on a 50-50 three way partnership known as Archigen Biotech. The rationale? A biosimilar to Roche’s blockbuster Rituxan, on which the small agency is constructed, “lacks commercial viability,” an official on the Korean CDMO stated, based on Korea Biomedical Evaluation. The pair has determined to cease growth of the copy regardless of having part Three knowledge.
3. Ex-AstraZeneca govt launches D3 Bio with $200M
George Chen, most lately AstraZeneca’s China R&D head, has arrange its personal store, D3 Bio. The corporate got here to life with $200 million from buyers resembling Sequoia Capital China, Temasek and WuXi AppTec’s company enterprise fund. The plan is to determine areas of unmet want in immunology and oncology and use present medical knowledge to seek out precision medication targets.
4. Viatris’ progress story hinges on M&A as China, Japan hold within the steadiness: analyst
Pfizer and Mylan have closed their generics merger, however the legacy Upjohn a part of the enterprise from Pfizer is topic to some uncertainties, primarily China’s value-based procurement program and Japan’s timing of Lyrica generics entry. Subsequently, RBC Capital Markets analyst Randall Stanicky argues the brand new firm ought to take into account M&A to spice up its progress outlook.
5. Celltrion plots $453M South Korean enlargement to help formidable biosimilar pipeline push: report
Celltrion, amid work on a COVID-19 antibody drug, plans to plow $453 million into constructing a 3rd manufacturing website and R&D heart at its Songdo, South Korea, complicated close to Seoul. The R&D portion is predicted to be accomplished by July 2022, whereas the plant might go surfing in June 2024 with an extra 60,000 liters of capability—a rise of about 33% from the corporate’s present quantity.
6. China’s Sinovac sees speedy immune response with COVID-19 shot in early trials
Sinovac’s COVID-19 vaccine candidate, CoronaVac, confirmed it might induce “a quick antibody response within four weeks of immunization,” based on researchers who printed the part half of ends in the journal Lancet Infectious Illnesses. The Chinese language agency is already testing the shot in part Three trials in numerous components of the world, together with one in Brazil that was briefly halted and shortly resumed.
7. Qiming Enterprise Companions boosts seventh fund to $1.2B, battling again in opposition to COVID-19 headwinds
China’s Qiming Enterprise Companions, an everyday life sciences investor, has collected $1.2 billion for its Fund VII, the most important within the nation this yr. The VC store has through the years picked up stakes in Schrödinger, CanSino Biologics and Zai Lab, amongst others.
8. As Urovant gears up for vibegron FDA choice, the biotech will get snapped up by Sumitovant Biopharma
In a $Three billion deal final yr, Japan’s Sumitomo Dainippon Pharma purchased 5 kids corporations from Roivant Sciences, with choices to accumulate six extra “vants,” to type a brand new firm known as Sumitovant Biopharma. Now, urology-focused Urovant has made its approach to the brand new agency because it nears an FDA choice knowledge for its lead asset, vibegron, in overactive bladder dysfunction.
9. Chinese language CRMO Pharmaron snaps up U.S. contract analysis firm Absorption Techniques
Beijing-based contract analysis and manufacturing firm Pharmaron is shelling out $147.5 million to accumulate U.S. preclinical CRO Absorption Techniques. The addition of Absorption additional expands Pharmaron’s international attain and boosts its work in DMPK/ADME and bioanalysis for each small and huge molecules and human PK prediction.